Q1 25 EPS
$0.20
MISS 12.32%
Est. $0.23
Q1 25 Revenue
$586.0M
BEAT +8.84%
Est. $538.4M
vs S&P Since Q1 25
-45.8%
TRAILING MARKET
HIMS -11.3% vs S&P +34.5%
Market Reaction
Did HIMS Beat Earnings? Q1 2025 Results
Hims & Hers Health posted a mixed but largely compelling Q1 2025, with revenue more than doubling year-over-year to $586.01 million, beating the $538.44 million consensus by 8.84%, even as earnings per share of $0.20 fell short of the $0.23 estimate … Read more Hims & Hers Health posted a mixed but largely compelling Q1 2025, with revenue more than doubling year-over-year to $586.01 million, beating the $538.44 million consensus by 8.84%, even as earnings per share of $0.20 fell short of the $0.23 estimate by 12.32%. The headline story was explosive growth in weight loss, where oral GLP-1 subscribers surged over 300% year-over-year, lifting monthly online revenue per subscriber 53% to $84.00 and pushing the total subscriber base to nearly 2.4 million. Net income expanded to $49.48 million from $11.13 million a year ago, while Adjusted EBITDA nearly tripled to $91.06 million. The stock saw notable volatility after management guided Q2 revenue to $530 million to $550 million, reflecting a near-term headwind as the company completes its transition away from commercially available semaglutide dosages by quarter's end. Full-year 2025 revenue guidance remains $2.30 billion to $2.40 billion, with Adjusted EBITDA guidance raised to $295 million to $335 million, underscoring management's confidence in durable, long-term growth.
Key Takeaways
- • 111% YoY revenue growth driven by new weight loss GLP-1 offerings and continued strength in existing specialties
- • Subscriber growth to 2.4 million (38% YoY) driven by increased traffic and improved customer experiences
- • Monthly online revenue per average subscriber increased 53% YoY to $84 due to GLP-1 uptake and product mix changes
- • 60% of subscribers now on personalized treatments
- • Over 80% personalized solution penetration in Men's and Women's Dermatology specialties
- • Oral weight loss subscribers grew over 300% year-over-year
- • Marketing leverage improved from 47% to 39% of revenue despite first Super Bowl commercial
- • Significant operating leverage achieved across all expense categories
HIMS YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
HIMS Revenue by Segment
With YoY comparisons, source: SEC Filings
HIMS Revenue by Geography
With YoY comparisons, source: SEC Filings
“We're starting 2025 with incredible momentum. Millions of people are turning to us for access to care that is personal, affordable, and has the potential to drive better outcomes.”
— Andrew Dudum, Q1 2025 Earnings Press Release
HIMS Earnings Trends
HIMS vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
HIMS EPS Trend
Earnings per share: estimate vs actual
HIMS Revenue Trend
Quarterly revenue: estimate vs actual
HIMS Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $0.03 | $-0.40 | -1,266.18% | $608.1M | -1.42% |
| Q4 25 BEAT FY | $0.04 | $0.08 | +92.31% | $617.8M | +0.09% |
| FY Full Year | $0.47 | $0.51 | +8.46% | $2.35B | +0.03% |
| Q3 25 MISS | $0.10 | $0.06 | -41.00% | $599.0M | +3.30% |
| Q2 25 MISS | $0.23 | $0.17 | -25.83% | $544.8M | -1.31% |
| Q1 25 MISS | $0.23 | $0.20 | -12.32% | $586.0M | +8.84% |
| Q2 22 MISS | $-0.09 | $-0.10 | -11.11% | $113.6M | +9.32% |